Cancer Letters
Volume 276, Issue 2 , Pages 180-188 , 18 April 2009

Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells

Received 12 July 2008 ,Revised 27 October 2008 ,Accepted 7 November 2008.

References 

  1. Ozols RF, Herbst RS, Colson YL. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J. Clin. Oncol. 2007;25:146–162
  2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127:S218–S224
  3. Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004;127:S248–S260
  4. Cammà C, Schepis F, Orlando A. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54
  5. Poolsup N, Suthisisang C, Prathanturarug S, Asawamekin A, Chanchareon U. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. J. Clin. Pharm. Ther. 2004;29:37–45
  6. Shen YC, Chen CF, Chiou WF. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Brit. J. Pharmacol. 2002;135:399–406
  7. Iruretagoyena MI, Tobar JA, González PA. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J. Pharmacol. Exp. Ther. 2005;312:366–372
  8. Calabrese C, Berman SH, Babish JG, Standish LJ. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother. Res. 2000;14:333–338
  9. Trivedi NP, Rawal UM, Patel BP. Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integr. Cancer Ther. 2007;6:271–280
  10. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J. Exp. Ther. Oncol. 2003;3:147–158
  11. Cheung HY, Cheung SH, Li J. Andrographolide isolated from Andrographis paniculata induces cell cycle arrest and mitochondrial-mediated apoptosis in human leukemic HL-60 cells. Planta. Med. 2005;71:1106–1111
  12. Li J, Cheung HY, Zhang Z, Chan GK, Fong WF. Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species. Eur. J. Pharmacol. 2007;568:31–44
  13. Zhou J, Zhang S, Ong CN, Shen HM. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem. Pharmacol. 2006;72:132–144
  14. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2006;2:458–466
  15. Yeh P, Kishony R. Networks from drug–drug surfaces. Mol. Syst. Biol. 2007;3:85
  16. Jackman AL, Kaye S, Workman P. The combination of cytotoxic and molecularly targeted therapies—can it be done?. Drug Discov. Today. 2004;1:445–454
  17. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003;22:9063–9074
  18. Park SH, Nam E, Park J. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann. Oncol. 2008;19:729–733
  19. Ychou M, Viret FK, Ramar A. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother. Pharmacol. 2008;62:195–201
  20. Kelsey CR, Chino JP, Willett CG. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:770–776
  21. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153–164
  22. Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene. 2004;23:2967–2975
  23. Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 2001;22:314–319
  24. Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol. Histopathol. 1998;13:521–530
  25. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic Bax and Bak: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–730
  26. Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J. Cell Biol. 2001;153:1265–1276
  27. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 1997;139:1281–1292
  28. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 2002;62:466–471
  29. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell Biol. 2000;20:929–935
  30. Marani M, Tenev T, Hancock D, Downward J, Lemoine NR. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol. Cell Biol. 2002;22:3577–3589
  31. Yamaguchi H, Wang HG. Bcl-XL protects BimEL-induced Bax conformational change and cytochrome c release independent of interacting with Bax or BimEL. J. Biol. Chem. 2002;277:41604–41612
  32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Method. 1983;65:55–63
  33. He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z. Induction of apoptosis by caffeine is mediated by the p53, Bax and caspase 3 pathways. Cancer Res. 2003;63:4396–4401
  34. Li P, Nijhawan D, Budihardjo I. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–489
  35. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Brit. J. Cancer. 1972;26:239–257
  36. Rello S, Stockert JC, Moreno V, Gamez A, Pacheco M, Juarranz A. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis. 2005;10:201–208
  37. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1–4
  38. Hu H, Jiang C, Schuster T, Li GX, Daniel PT, Lü J. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther. 2006;5:1873–1882
  39. Backus HH, Dukers DF, van Groeningen CJ. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann. Oncol. 2001;12:209–216
  40. Yamamoto T, Nagano H, Sakon M. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin. Cancer Res. 2004;10:7884–7895
  41. Kuwana T, Bouchier-Hayes L, Chipuk JE. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell. 2005;17:525–535
  42. Chipuk JE, Kuwana T, Bouchier-Hayes L. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–1014
  43. Hockenbery DM, Giedt CD, O’Neill JW, Manion MK, Banker DE. Mitochondria and apoptosis: new therapeutic targets. Adv. Cancer Res. 2002;85:203–242
  44. Ehrhardt H, Häcker S, Wittmann S. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene. 2008;27:783–793
  45. Carmody RJ, Cotter TG. Signalling apoptosis: a radical approach. Redox. Rep. 2001;6:77–90
  46. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol. Biochem. 2001;11:173–186
  47. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 1996;93:11848–11852

PII: S0304-3835(08)00886-0

doi: 10.1016/j.canlet.2008.11.015

Cancer Letters
Volume 276, Issue 2 , Pages 180-188 , 18 April 2009

Article Tools

* Image Usage & Resolution